SSA
HRTX icon

Schonfeld Strategic Advisors’s Heron Therapeutics HRTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-38,700
Closed -$96.8K – 2327
2022
Q4 		$96.8K Sell
38,700
-55,634
-59% -$179K ﹤0.01% 2190
2022
Q3 		$397K Buy
+94,334
New +$369K ﹤0.01% 1911
2022
Q1 		– Sell
-28,900
Closed -$264K – 2724
2021
Q4 		$264K Sell
28,900
-21,700
-43% -$222K ﹤0.01% 1566
2021
Q3 		$541K Buy
+50,600
New +$616K 0.01% 1222

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Schonfeld Strategic Advisors's HRTX Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of Heron Therapeutics (HRTX) in Q1 2023, closing a stake of 38,700 shares — an estimated $96.8K sold.

Schonfeld Strategic Advisors first reported a position in HRTX in Q3 2021 and held it in 4 quarters. The position peaked at $541K in Q3 2021. 162 funds tracked by Wall St. Rank hold HRTX as of Q1 2023.

  • Schonfeld Strategic Advisors reported no remaining Heron Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 38,700 Heron Therapeutics shares in Q1 2023, an estimated $96.8K.
  • Schonfeld Strategic Advisors first reported a position in Heron Therapeutics in Q3 2021 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Heron Therapeutics position peaked at $541K in Q3 2021.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.